Generic Active Pharmaceutical Ingredients (API) manufacturer Cambrex Corporation recently installed several continuous flow reactor platforms at its High Point, NC facility, the company announced in a recent press release.
Cambrex’s purchase of the new technology boosts the firm’s developmental capabilities for new processes and compliments its recent opening of a dedicated commercial-scale continuous flow production unit at its Karlskoga, Sweden plant.
“We are seeing significant interest in continuous flow development and production, predominantly from established pharmaceutical companies looking for process improvements in Phase II,” Brian Swierenga, site and operations director for Cambrex’s High Point site, said in the release.
The company also recently completed construction on a $3.2 million 11,000-sq-ft analytical laboratory at the North Carolina facility and a pilot plant expansion project that added a new reactor suite to the site.
“We have designed the new laboratory and GMP pilot plant with maximum flexibility in mind, allowing us to explore the possibilities for both new and existing production projects, either on a FTE or custom contract basis,” said Swierenga.
Cambrex’s Director of Engineering R&D Dr. Shawn Conway is slated to lead the new development center at High Point backed by a group of chemical engineers.
The East Rutherford, NJ-based company also said it is in the process another $25 million expansion project at its manufacturing plant for highly potent APIs (HPAPIs) in Charles City, IA.